ClinicalTrials.gg
Not yet recruitingNCT07512076Updated Apr 6, 2026

A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer

A Phase 2 interventional study of Enzalutamide Dose Escalation and Standard of Care in Prostate Cancer Patients, Elderly Patients and Pharmacokinetic Study, sponsored by Sunnybrook Health Sciences Centre. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Sunnybrook Health Sciences Centre · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre — 8 open to participants now, 15 under way, 1 of them phase 3. Prostatic Neoplasms · Sunnybrook Health Sciences Centre.

Planned enrollment
27th of 36
26 · median 30
Started
2026
with 2 others
Phase 2
3 of 39
1 open now
Primary completion
2027-07
later than 6 of 14 live
Registered
37th of 39
by date

Among the 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre, this one is the 27th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 6 of the 14 other live ones, and was the 37th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Prostatic Neoplasms by Sunnybrook Health Sciences Centre, or all of them as a file.
02

Study summary

This is a phase II, single-centre, pragmatic, non-randomized, dose escalation study to evaluate optimal dose levels of enzalutamide in elderly patients using pharmacokinetic blood sampling concentrations.

Read the detailed description

Enzalutamide is an androgen receptor pathway inhibitor (ARPI) drug that is commonly used in prostate cancer. It is safe, effective, and is generally well tolerated by patients at the standard dose of 160mg, however researchers have seen that it may cause unfavorable side effects in elderly patients 75 and older such as fatigue and cognitive impairment that impact their quality of life more significantly than those under 75.

To date there is limited research comparing differences in side effects and quality of life experienced by elderly patients on standard versus a lower dose of enzalutamide. Dose reductions are common, particularly in elderly patients, although they are not explicitly recommended on the drug label, and as a result this study seeks to build on the existing research and practice experience to evaluate how enzalutamide is metabolized in elderly patients and whether this difference warrants different dosing standards in these patients.

03

Conditions studied

  • Prostate Cancer Patients
  • Elderly Patients
  • Pharmacokinetic Study

Browse trials for

Keywords

  • prostate cancer
  • enzalutamide
  • elderly patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main Cohort:

  1. Male aged 75 years or older.
  2. Signed Form
  3. Advanced prostate cancer with a Health Canada approved indication for enzalutamide amongst the following:

    1. High-risk biochemical recurrent hormone sensitive prostate cancer (high risk definition: PSA doubling time of ≤9 months and a PSA level of ≥2 ng per milliliter above nadir after radiation therapy or ≥1 ng per milliliter after radical prostatectomy with or without postoperative radiation therapy).
    2. castration-sensitive prostate cancer.
    3. Non-metastatic castration-resistant prostate cancer (M0CRPC) with a PSA doubling time of ≤9 months
  4. Participants must receive concomitant androgen deprivation therapy with either a Luteinizing hormone-releasing hormone (LHRH) antagonist or agonist, or have had bilateral orchiectomy.
  5. Participant is capable, in the opinion of the investigator, of completing all study assessments and procedures, including blood draws for PK sampling according to the required schedule as per the study protocol as well as PROs.

    1. Note, for patients who speak a language other than English, PROs may be completed with the help of an interpreter, or translated PROs may be substituted, if available in the patient's primary language.

Control Cohort:

  1. Age \< 70 years
  2. Receiving enzalutamide for advanced prostate, for any indication as per Product Monograph
  3. Receiving the same dose of enzalutamide taken daily and fully compliant for ≥ 29 days
  4. Signed Informed Consent Form

Exclusion criteria

Exclusion Criteria:

Main Cohort:

  1. castration-resistant prostate cancer
  2. Pain related to bone metastasis requiring the use of opioid analgesics
  3. Impending spinal cord compression related to metastasis to vertebral column
  4. Painful femoral neck or any other metastasis judged to be at risk of short-term pathological fracture in the investigator's opinion
  5. Co-administration of medications which are moderate to strong CYP2C8 inducers or inhibitors
  6. Co-administration of medications which are moderate to strong inducers or inhibitors
  7. History of seizure disorder
  8. History of moderate-severe dementia
  9. Performance status > 2
  10. Uncontrolled hypertension (defined as sustained systolic blood pressure above 160 and/or diastolic above 100 despite the adequate use of antihypertensive medication)
  11. Participants with a known history of dementia, seizure disorder, intracranial lesions, moderate to severe hepatic impairment, stage ≥ 3 chronic renal failure or stroke will also be excluded

Control Cohort:

  1. Unable to provide written
  2. Receiving a medication which is a moderate-strong CYP2C8 or CYP3A4 inducer or inhibitor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Main Cohort

    Participants 75 years and older who have have a confirmed diagnosis of advanced prostate cancer, and are suitable candidates to receive enzalutamide but have not started treatment with the drug yet.

    Drug: Enzalutamide Dose Escalation

  • Active comparator
    Control Cohort

    The control cohort will enroll participants that are under 70 years old, and are currently receiving enzalutamide for a period of more than 29 days.

    Drug: Standard of Care

Interventions

  • DrugEnzalutamide Dose Escalation

    Participants will be allocated to receive one of 4 dose levels of enzalutamide; * Level 1: 40mg * Level 2: 80mg * Level 3: 120mg * Level 4: 160mg There will be 4 participants per dose level. After 8 weeks of treatment at the initial dose level, the study doctor will review treatment progress and may escalate to a higher dose level at their discretion. For each dose level participants move up to (if applicable), they will repeat this same 8 weeks of treatment and evaluation process.

  • DrugStandard of Care

    Participants will continue to receive enzalutamide per standard of care.

06

What researchers measure

Primary outcomes

  1. Enzalutamide Plasma Levels

    To compare enzalutamide plasma concentrations in patients ≥ 75 years of age with younger patients at various dose levels.

    Time frame: At day 29 and 57 of all applicable dose levels, up to 32 weeks maximum (4 levels, 8 weeks apart)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jul 2027, 15 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 15 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 6, 2026
StartEst.
Apr 2026
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07512076
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Apr 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Daniel Khalaf, MD
Contact
daniel.khalaf@sunnybrook.ca
416-480-4617
Elyse Watkins
Contact
elyse.watkins@sunnybrook.ca
Daniel Khalaf, MD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion